As of May 27, 2025, SpringWorks Therapeutics Inc (SWTX) reports a ROA (Return on Assets) of -43.95%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of SpringWorks Therapeutics Inc's ROA (Return on Assets)
Over recent years, SpringWorks Therapeutics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -43.95% |
| 2023-12-31 | -44.79% |
| 2022-12-31 | -44.02% |
| 2021-12-31 | -38.43% |
| 2020-12-31 | -7.91% |
This slight upward trend highlights how SpringWorks Therapeutics Inc manages its efficiency in using assets to generate earnings over time.
Comparing SpringWorks Therapeutics Inc's ROA (Return on Assets) to Peers
To better understand SpringWorks Therapeutics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| SpringWorks Therapeutics Inc (SWTX) | -43.95% |
| Arena Pharmaceuticals Inc (ARNA) | 33.86% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
| Gilead Sciences Inc (GILD) | 0.81% |
Compared to its competitors, SpringWorks Therapeutics Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.